---
layout: default
title: Milrinone
parent: 僅模型預測 (L5)
nav_order: 669
evidence_level: L5
indication_count: 10
---

# Milrinone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Milrinone: From Acute Heart Failure to Alopecia

## One-Sentence Summary

Milrinone is a phosphodiesterase-3 (PDE3) inhibitor globally established as a short-term intravenous inotrope/vasodilator for acute decompensated heart failure, though it is **not currently registered or marketed in Singapore** (0 HSA licenses). The TxGNN model's top-ranked prediction for this drug is **Alopecia**, but this candidate is currently supported by **0 clinical trials** and **0 publications** — it is a pure model-score prediction with no corroborating evidence.

> **Note:** This evidence pack also contains several other TxGNN-predicted indications for Milrinone with substantially stronger evidence — notably **Congestive Heart Failure** (L1, 50 trials, 20 publications, "Proceed with Guardrails" — effectively confirming an already-known use rather than a novel repurposing), **Acute Pulmonary Heart Disease** (L2, 27 trials, 20 publications, "Research Question"), and **Headache Disorder** (L4, case-report/case-series literature on RCVS, "Research Question"). This report focuses on the top-ranked candidate (Alopecia) per the evaluation template; reviewers may wish to prioritize those higher-evidence candidates for follow-up instead.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not registered in Singapore (0 HSA licenses; no approved label text available). Globally, Milrinone's established use is short-term IV support in acute decompensated heart failure / cardiogenic shock. |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Singapore Market Status | 未上市 (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (marked as a Data Gap, DG002 — High severity). Based on known pharmacology, Milrinone is a bipyridine-class PDE3 inhibitor: it blocks breakdown of cyclic AMP (cAMP), producing positive inotropy in cardiac muscle and vasodilation in peripheral/pulmonary vasculature. This mechanism is well proven for acute heart failure but has no established connection to hair follicle biology.

The repurposing rationale supplied for this candidate is explicitly speculative: cAMP signaling is theoretically involved in regulating the hair follicle cycle (by loose analogy to other PDE- or ion-channel-related hair-growth agents such as minoxidil), but minoxidil's actual mechanism differs from PDE3 inhibition, and no direct literature or trial data link Milrinone to alopecia. The mechanistic link should be treated as a hypothesis generated purely from knowledge-graph proximity, not as pharmacologically validated reasoning.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Singapore Market Information

Milrinone is not currently registered or marketed in Singapore — HSA licensing data shows 0 total licenses and no product listings.

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all marked as Data Gaps in this evidence pack; DG001 — TFDA/HSA label warnings/contraindications — is flagged **Blocking** severity, meaning safety review cannot proceed until this is resolved.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN score for Alopecia is high, but there is zero clinical trial or literature support, and the proposed mechanistic link is speculative/analogical rather than evidence-based. This candidate remains at decision stage S0 and does not meet the threshold to advance.

**To proceed, the following is needed:**
- MOA confirmation via DrugBank API query (DG002, High severity)
- TFDA/HSA label warnings and contraindications (DG001, **Blocking** — required before any S1 safety review)
- Preclinical or mechanistic studies specifically linking PDE3 inhibition/cAMP signaling to hair follicle cycling
- Any hypothesis-generating case reports or exploratory trials in alopecia populations
- Consider re-scoping this evaluation toward the higher-evidence candidates in the same pack (Congestive Heart Failure, Acute Pulmonary Heart Disease, Headache Disorder) if the goal is near-term actionable repurposing
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

